axi-cabtagene ciloleucel治疗原发性纵隔大B细胞淋巴瘤的疗效与弥漫性大B细胞淋巴瘤相比更具优势：一项GLA/DRST注册研究。 - Suppr

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study.

作者信息

Schubert Maria-Luisa, Bethge Wolfgang A, Ayuk Francis A, von Bonin Malte, Vucinic Vladan, Wagner-Drouet Eva Marie, Subklewe Marion, Baldus Claudia D, Glass Bertram, Marks Reinhard, Mougiakakos Dimitrios, Schroers Roland, Stelljes Matthias, Topp Max S, Wulf Gerald, Kröger Nicolaus, Dreger Peter

机构信息

Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany.

Department of Hematology and Oncology, University Hospital Tuebingen, Tuebingen, Germany.

出版信息

Blood Adv. 2023 Oct 24;7(20):6191-6195. doi: 10.1182/bloodadvances.2023011203.

DOI:10.1182/bloodadvances.2023011203

PMID:37603595

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10582836/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9886/10582836/6068112c21b5/BLOODA_ADV-2023-011203-gr1.jpg

相似文献

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study.

Blood Adv. 2023 Oct 24;7(20):6191-6195. doi: 10.1182/bloodadvances.2023011203.

Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.

Leuk Lymphoma. 2018 Aug;59(8):1785-1796. doi: 10.1080/10428194.2017.1387905. Epub 2017 Oct 23.

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

JAMA Netw Open. 2022 Dec 1;5(12):e2245956. doi: 10.1001/jamanetworkopen.2022.45956.

Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.

JAMA Oncol. 2020 Feb 1;6(2):281-290. doi: 10.1001/jamaoncol.2019.3869.

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8.

Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.

Transplant Cell Ther. 2023 Jun;29(6):349.e1-349.e8. doi: 10.1016/j.jtct.2023.02.021. Epub 2023 Mar 5.

Current and emerging treatment options in primary mediastinal B-cell lymphoma.

Ther Adv Hematol. 2021 Oct 8;12:20406207211048959. doi: 10.1177/20406207211048959. eCollection 2021.

Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.

Expert Rev Anticancer Ther. 2022 Sep;22(9):903-914. doi: 10.1080/14737140.2022.2096009. Epub 2022 Aug 5.

引用本文的文献

Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New.

Hematol Rep. 2025 Apr 28;17(3):23. doi: 10.3390/hematolrep17030023.

CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma.

Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02615-0.

Real-world data analysis of survival outcomes of patients with primary mediastinal large B-cell lymphoma treated with immunochemotherapy: the role of consolidative radiation therapy.

Blood Res. 2025 Apr 22;60(1):27. doi: 10.1007/s44313-025-00076-4.

Long-Term Outcomes and Management Strategies With DA-R-EPOCH in Primary Mediastinal B-Cell Lymphoma: Insights From a Single-Center Experience.

Hematol Oncol. 2025 May;43(3):e70060. doi: 10.1002/hon.70060.

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Blood Adv. 2025 May 13;9(9):2232-2246. doi: 10.1182/bloodadvances.2024015577.

Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell Lymphoma.

J Clin Med. 2025 Feb 11;14(4):1191. doi: 10.3390/jcm14041191.

Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry.

Hemasphere. 2025 Feb 18;9(2):e70091. doi: 10.1002/hem3.70091. eCollection 2025 Feb.

The Role of the Tumor Microenvironment in T-Cell Redirecting Therapies of Large B-Cell Lymphoma: Lessons Learned from CAR-T to Bispecific Antibodies.

Cancers (Basel). 2025 Jan 20;17(2):317. doi: 10.3390/cancers17020317.

Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.

Haematologica. 2024 Sep 1;109(9):3019-3023. doi: 10.3324/haematol.2023.284689.

Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.

Haematologica. 2024 Aug 1;109(8):2716-2720. doi: 10.3324/haematol.2024.285010.

本文引用的文献

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.

Blood Adv. 2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016.

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893.

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.

Blood Adv. 2023 Jun 27;7(12):2872-2883. doi: 10.1182/bloodadvances.2022009019.

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.

Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.

Blood. 2022 Jul 28;140(4):349-358. doi: 10.1182/blood.2021015209.

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort.

Exp Hematol Oncol. 2021 Dec 9;10(1):55. doi: 10.1186/s40164-021-00248-9.

Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma.

Blood Adv. 2021 Sep 28;5(18):3563-3567. doi: 10.1182/bloodadvances.2021004880.

Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics.

Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):e865-e875. doi: 10.1016/j.clml.2021.06.012. Epub 2021 Jun 24.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献